A detailed history of Mirae Asset Global Etfs Holdings Ltd. transactions in Uro Gen Pharma Ltd. stock. As of the latest transaction made, Mirae Asset Global Etfs Holdings Ltd. holds 21,667 shares of URGN stock, worth $200,853. This represents 0.0% of its overall portfolio holdings.

Number of Shares
21,667
Previous 20,698 4.68%
Holding current value
$200,853
Previous $262,000 12.21%
% of portfolio
0.0%
Previous 0.0%

Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2024

Feb 14, 2025

BUY
$10.52 - $13.11 $10,193 - $12,703
969 Added 4.68%
21,667 $230,000
Q3 2024

Nov 14, 2024

BUY
$12.7 - $17.92 $76,898 - $108,505
6,055 Added 41.35%
20,698 $262,000
Q2 2024

Aug 14, 2024

BUY
$12.72 - $19.2 $186,258 - $281,145
14,643 New
14,643 $245,000

Others Institutions Holding URGN

About UroGen Pharma Ltd.


  • Ticker URGN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 22,740,500
  • Market Cap $211M
  • Description
  • UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization novel solutions for specialty cancers and urothelial diseases. It offers RTGel, a polymeric biocompatible and reverse thermal gelation hydrogel to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution. The company's lead...
More about URGN
Track This Portfolio

Track Mirae Asset Global Etfs Holdings Ltd. Portfolio

Follow Mirae Asset Global Etfs Holdings Ltd. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Mirae Asset Global Etfs Holdings Ltd., based on Form 13F filings with the SEC.

News

Stay updated on Mirae Asset Global Etfs Holdings Ltd. with notifications on news.